ESKETAMINE

Brand name:

• Spravato®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Treatment resistant depression

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New PBS listing (Standard Re-entry Pathway)

Comment:

--

Submission sponsor:

JANSSEN-CILAG PTY LTD

Other PBAC consideration:

• ESKETAMINE
• ESKETAMINE
• ESKETAMINE

Submission received for:

July 2024 PBAC meeting

Opportunity for consumer comment:

Open 03/04/2024 and close 29/05/2024 (see PBS Website)

PBAC meeting:

Held on 10/07/2024

PBAC outcome published:

Deferred (see PBAC Outcomes)

5Lodgement of required documentation:

Has not yet commenced

6Agreement to listing arrangements:

Has not yet commenced

7Government processes:

Has not yet commenced

8Medicine listed on the PBS:

Has not yet occurred

---